needed effects
liraglutide
active ingredient
saxenda
unwanted side effects
medical attention
liraglutide side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
chronic weight management
nausea
diarrhea
constipation
vomiting
dyspepsia
abdominal pain
upper abdominal pain
gastroesophageal reflux disease
abdominal distension
eructation
flatulence
dry mouth
gastroenteritis
viral gastroenteritis
lipase
acute pancreatitis
acute gallbladder diseasetype diabetes mellitus
nausea
diarrhea
vomiting
constipation
dyspepsia
abdominal pain
gastritis
flatulence
abdominal discomfort
toothacherare
intestinal obstructionpostmarketing reports
necrotizing pancreatitis
including fatalities
chronic weight management
percentage of patients
reporting nausea
treatment
most gastrointestinal events
discontinuation
acute pancreatitis
liraglutide-treated patients
placebo patients in clinical trials
additional cases
liraglutide-treated patients
patients
trial
off-treatment follow-up period
acute gallbladder disease
liraglutide-treated patients
clinical trials
rapid weight loss
risk of cholelithiasis
accounting for the degree of weight loss
incidence of acute gallbladder disease
liraglutide-treated patients
type diabetes mellitusthere
been postmarketing reports of acute hemorrhagic
necrotizing pancreatitis
including fatalities
clinical trials
cases of pancreatitis
liraglutide
treated patients
case in the comparator
glimepiride
group
patients
other risk factors for pancreatitis
history of cholelithiasis
alcohol abuse
chronic weight management
hypoglycemia in type diabetes
decreased appetitetype diabetes mellitus
hypoglycemia
combination with a sulfonylurea
hypoglycemia
anorexia
appetiteuncommon
dehydrationpostmarketing reports
dehydration
nausea
vomiting
diarrhea
chronic weight management
patients with type diabetes mellitus
drug for chronic weight management
severe hypoglycemia
liraglutide-treated patients
patients
receiving
sulfonylurea
patients
drug in combination with a sulfonylurea
symptomatic hypoglycemia
patients
dose of sulfonylurea
start of the trial
patients
taking
sulfonylurea
symptomatic hypoglycemia
patients
type diabetes mellitus
major episodes of hypoglycemia
clinical trials in which liraglutide
monotherapy
combination with a sulfonylurea
hypoglycemia
headache
dizzinessfrequency
dysgeusia
type diabetes mellitus
nasopharyngitis
bronchitis
upper respiratory infection
reported adverse events
chronic weight management
clinical trials
nausea
hypoglycemia
diarrhea
constipation
vomiting
headache
appetite
dyspepsia
fatigue
dizziness
abdominal pain
lipase
reported adverse events
type diabetes mellitus
clinical trials
headache
nausea
diarrhea
active ingredient
saxenda
antibody formation
chronic weight management
increases in mean
resting heart ratecommon
hypotensionuncommon
cardiac conduction disorder
tachycardiatype diabetes mellitus
increased heart rate
chronic weight management
cardiac conduction disorders
first degree
atrioventricular block
right bundle branch block
bundle branch block
increases in mean
resting heart rate
beats per minute
bpm
clinical trials
increases
bpm at consecutive visits
liraglutide-treated patients
placebo group
resting heart rate
exceeding bpm
liraglutide-treated patients
placebo patients
tachycardia
liraglutide-treated patients
placebo patients
monitoring heart rate
hours
liraglutide treatment
higher heart rate than placebo
clinical significance of this
urinary tract infection
injection site erythema
injection site reaction
common injection site reactions
erythema
pruritus
rash at the injection site
frequency
development of anti-liraglutide
active ingredient
saxenda
antibodies
urticariapostmarketing reports
serious hypersensitivity reactions
anaphylactic reactions
angioedema
drug
animal studies
clinical trials
postmarketing reports of acute renal failure
worsening of chronic renal failure
requiring dialysis
majority of reports
patients
experienced nausea
vomiting
diarrhea
dehydration
type diabetes mellitus
renal impairment
acute renal failurepostmarketing reports
acute renal failure
worsening of chronic renal failure
requiring dialysis
serum creatinine
rashuncommon
urticaria
pruritus
increased blood calcitonin levelsuncommon
goiter
fatigueuncommon
asthenia
malaise
chronic weight management
fatigue
asthenia
first weeks
gastrointestinal events
chronic weight management
clinical trials
patients
receiving liraglutide
active ingredient
saxenda
suicidal ideation
suicide
reports in patients
receiving placebo
chronic weight management
insomnia
anxietyuncommon
suicidal ideationvery
suicide attempt
chronic weight management
alt
frequency
ast increasedtype diabetes mellitus
postmarketing reports
elevations of liver enzymes
hyperbilirubinemia
cholestasis
hepatitis
chronic weight management
breast cancer
clinical trials
liraglutide-treated patients
breast cancer
placebo patients
few cases
drug treatment
insufficient data
drug
effect on preexisting breast neoplasia
papillary thyroid cancer
clinical trials
liraglutide-treated patients
papillary thyroid carcinoma
cases in placebo patients
colorectal neoplasms
clinical trials
liraglutide-treated patients
benign colorectal neoplasms
placebo patients
malignant colorectal carcinoma
liraglutide-treated patients
type diabetes mellitus
clinical trials
cases of thyroid c-cell hyperplasia
liraglutide-treated patients
cases in the comparator-treated group
case per patient-years
medullary thyroid carcinoma
patient in the comparator group
pretreatment serum calcitonin concentrations
ng/l
suggesting preexisting disease
study
protocol-specified serum calcitonin measurements
cases of thyroid c-cell hyperplasia
thyroidectomy
abnormal calcitonin levels
patients with thyroid c-cell hyperplasia
elevated calcitonin concentrations at baseline
trial
patient
liraglutide-treated group
comparator group
elevated calcitonin concentrations
treatment
chronic weight management
benign colorectal neoplasms
papillary thyroid cancer
breast cancer
malignant colorectal carcinomatype diabetes mellitus
thyroid neoplasms frequency
thyroid c-cell hyperplasiapostmarketing reports
medullary thyroid cancer
side effects of saxenda
fda
healthcare professional for medical advice
bladder pain
cloudy urine
cough or hoarseness
diarrhea
burning
painful urination
fever or chills
frequent urge
general feeling of discomfort
illness
headache
joint pain
loss of appetite
side pain
muscle aches
pains
nausea
runny nose
shivering
sore throat
sweating
trouble sleeping
unusual tiredness
weakness
vomiting
blurred vision
dizziness
nervousness
pounding in the ears
fast heartbeat
anxiety
cold sweats
coma
confusion
cool, pale skin
depression
hives
welts
itching
skin rash
increased hunger
hive-like swelling on the face
eyelids
lips
tongue
throat
hands
legs
feet
sex organs
nightmares
redness of the skin
seizures
shakiness
slurred speech
agitation
clay-colored stools
confusion
dark urine
decreased urine output
depression
difficulty with swallowing
hostility
irritability
lethargy
muscle twitching
puffiness
swelling of the eyelids
eyes
face
lips
tongue
rapid weight gain
stupor
swelling of the face
ankles
hands
tightness in the chest
unpleasant breath odor
vomiting of blood
yellow eyes
skin
stomach cramps
discomfort
pain
acid
sour stomach
back pain
belching
body aches
pain
constipation
decreased appetite
heartburn
indigestion
loss of voice
pain
tenderness around the eyes
cheekbones
sneezing
stuffy nose
swollen mouth
tongue
unpleasant taste
urge
bowel movement
weight loss
bleeding
blistering
burning
coldness
discoloration of the skin
feeling of pressure
hives
infection
inflammation
itching
lumps
numbness
pain
rash
redness
scarring
soreness
swelling
tenderness
tingling
ulceration
warmth at the injection site